7-Methyltryptamine (7-Me-T or 7-methyl-T; developmental code name PAL-286) is a serotonin receptor modulator and monoamine releasing agent of the tryptamine family. It is the 7-methyl derivative of tryptamine.
The drug acts as a potent full agonist of the serotonin 5-HT2A receptor, with an of 44.7nM and an of 103%. It shows 6-fold lower potency as a serotonin 5-HT2A receptor agonist compared to tryptamine itself. 7-Methyltryptamine also shows affinity for the serotonin 5-HT1D receptor, but has greatly reduced affinity compared to tryptamine ( = 1,900nM and 57nM, respectively; 33-fold lower). It shows extremely weak affinity for the dizocilpine (MK-801) site of the NMDA receptor ( = ~650,000nM). In addition to its serotonin 5-HT2A receptor agonism, 7-methyltryptamine is a serotonin releasing agent (SRA), with values for induction of monoamine release of 23.7nM for serotonin, 3,380nM for dopamine, and >10,000nM for norepinephrine in rat brain synaptosomes.
Tryptamines without substitutions at the amine or alpha carbon, such as tryptamine, serotonin (5-hydroxytryptamine; 5-HT), and 5-methoxytryptamine (5-MeO-T), are known to be very rapidly metabolized and thereby inactivated by monoamine oxidase A (MAO-A) in vivo and to have very short elimination half-lives. However, given intravenously at sufficiently high doses, tryptamine is still known to be able to produce weak and short-lived psychoactive effects in humans.
The chemical synthesis of 7-methyltryptamine has been described. The chemical identification of 7-methyltryptamine has been described as well.
7-Methyltryptamine was first described in the scientific literature by 1956. Its pharmacology was subsequently assessed in greater detail in 2014.
See also Substituted tryptamine 7-Methyl-DMT 7-Methyl-5-MeO-DMT 7-Methylpsilocin 7-Methoxytryptamine
References
External links 7-Methyl-T - Isomer Design